Tango Therapeutics, Inc.
TNGX
$10.08
-$0.34-3.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1,591.64% | -41.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,591.64% | -41.01% | |||
| Cost of Revenue | -6.07% | -9.97% | |||
| Gross Profit | 177.62% | 4.59% | |||
| SG&A Expenses | -21.31% | -1.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.99% | -7.88% | |||
| Operating Income | 134.35% | 3.68% | |||
| Income Before Tax | 140.89% | 2.57% | |||
| Income Tax Expenses | -128.57% | 2.94% | |||
| Earnings from Continuing Operations | 140.88% | 2.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 140.88% | 2.57% | |||
| EBIT | 134.35% | 3.68% | |||
| EBITDA | 136.26% | 3.74% | |||
| EPS Basic | 140.71% | 2.77% | |||
| Normalized Basic EPS | 140.73% | 4.32% | |||
| EPS Diluted | 136.98% | 2.77% | |||
| Normalized Diluted EPS | 138.36% | 4.32% | |||
| Average Basic Shares Outstanding | 0.38% | 0.22% | |||
| Average Diluted Shares Outstanding | 6.55% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||